SARS-CoV-2 Monoclonal Antibody Treatment Followed by Vaccination Shifts Human Memory B-Cell Epitope Recognition, Suggesting Antibody Feedback.
Saved in:
| Title: | SARS-CoV-2 Monoclonal Antibody Treatment Followed by Vaccination Shifts Human Memory B-Cell Epitope Recognition, Suggesting Antibody Feedback. |
|---|---|
| Authors: | Bloom N; Center for Vaccine Innovation, La Jolla Institute for Immunology., Ramirez SI; Center for Vaccine Innovation, La Jolla Institute for Immunology.; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla., Cohn H; Department of Microbiology.; Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New York, New York., Parikh UM; Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania., Heaps A; Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania., Sieg SF; Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve School of Medicine, Cleveland, Ohio., Greninger A; Department of Medicine, University of Washington, Seattle., Ritz J; Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Moser C; Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Eron JJ; Department of Medicine, University of North Carolina at Chapel Hill School of Medicine., Bajic G; Department of Microbiology., Currier JS; Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles., Klekotka P; Eli Lilly and Company, San Diego., Wohl DA; Department of Medicine, University of North Carolina at Chapel Hill School of Medicine., Daar ES; Lundquist Institute at Harbor, University of California, Los Angeles Medical Center, Torrance., Li J; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Hughes MD; Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Chew KW; Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles., Smith DM; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla., Crotty S; Center for Vaccine Innovation, La Jolla Institute for Immunology.; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla., Coelho CH; Department of Microbiology.; Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New York, New York.; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York. |
| Corporate Authors: | Accelerating COVID-19 Therapeutic Interventions and Vaccines–2/A5401 (ACTIV-2/A5401) Study Team |
| Source: | The Journal of infectious diseases [J Infect Dis] 2024 Nov 15; Vol. 230 (5), pp. 1187-1196. |
| Publication Type: | Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1537-6613 |
|---|---|
| DOI: | 10.1093/infdis/jiae371 |
